About this trial
The purpose of this study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS).
Patient Profile
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St Vincents University Hospital, and University Hospital Galway
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | R3767-ONC-2055 |
|---|---|
| Number: | 22-25 |
| Full Title: | A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma |
| Principal Investigator: | Prof Derek Power |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Regeneron |
| Recruitment Started: |
Global: 16-Jan-2023 Ireland: Q4 2023 |
| Global Recruitment Target: | 1530 |
|---|---|
| Ireland Recruitment Target: | 27 |